JAZZ Jazz Pharmaceuticals plc

128.44
+0.76  (+1%)
Previous Close 127.68
Open 128.27
Price To Book 2.66
Market Cap 7328238090
Shares 57,055,731
Volume 567,817
Short Ratio
Av. Daily Volume 676,757

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released March 26, 2019 met primary endpoint.
JZP-258
Cataplexy and Excessive Daytime Sleepiness in Narcolepsy
CRL received October 11, 2010.
JZP-6
Fibromyalgia
Phase 2 enrollment initiation announced February 8, 2017.
JZP-110
Excessive Sleepiness in Parkinson's Disease
FDA Approval announced October 26, 2018.
Xyrem
Pediatric narcolepsy patients with cataplexy
Phase 3 data released March 20, 2017 - primary endpoints met.
JZP-110
Excessive sleepiness associated with obstructive sleep apnea
FDA Approval announced March 20, 2019.
JZP-110
Excessive sleepiness associated with narcolepsy
Phase 3 dosing initiation announced January 18, 2017.
Defibrotide
VOD in high-risk patients following hematopoietic stem cell transplantation
Approval announced August 3, 2017.
Vyxeos
Acute myeloid leukemia
Phase 2 commencement of enrollment announced February 23, 2018.
Defibrotide
acute Graft-versus-Host-Disease (aGvHD)
Phase 3 commencement of enrolment announced November 29, 2018.
JZP-258
Idiopathic Hypersomnia

Latest News

  1. Are Hedge Funds Right About Jazz Pharmaceuticals?
  2. JAZZ vs. ZTS: Which Stock Is the Better Value Option?
  3. Should We Be Cautious About Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) ROE Of 16%?
  4. 3 Reasons Why Jazz (JAZZ) Is a Great Growth Stock
  5. Concert Pharma Initiates Early-Stage Schizophrenia Study
  6. See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
  7. Drugmakers Jazz, Alexion, Lundbeck to pay $123 million to resolve U.S. charity kickback probe
  8. Drugmakers Jazz, Alexion, Lundbeck to pay $123 mln to resolve U.S. charity kickback probe
  9. Jazz Pharma, Alexion and Lundbeck to pay $122.6 million to resolve kickback allegations
  10. Stocks That Would Have Made You Rich Today
  11. Jazz (JAZZ) Down 0.4% Since Last Earnings Report: Can It Rebound?
  12. Jazz's Xyrem Follow-On Drug Succeeds in Phase III Study
  13. The Daily Biotech Pulse: FDA Nod For Novartis, Jazz Positive Late-Stage Data For Sleep Disorder Drug, Genfit IPO
  14. Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of JZP-258 in Adult Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepiness
  15. What Should Investors Know About The Future Of Jazz Pharmaceuticals plc's (NASDAQ:JAZZ)?
  16. Health Care Digest: Genentech's tumor-agnostic cancer drug, Novartis' East Bay option and more
  17. Analysts Reduce Jazz Pharmaceuticals’ Target Price in March
  18. The Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering
  19. FDA approves Jazz Pharmaceuticals sleep disorder drug